Novartis Unit Seeks £11.3M Damages Over Invalidated Patent

Law360, London (October 8, 2020, 9:12 PM BST) -- A Novartis subsidiary slapped a Pfizer unit with a claim in the U.K. for more than £11.3 million ($14.6 million) in damages it says it suffered from infringement litigation over a patent for the blockbuster drug Lyrica that was later invalidated by the U.K. Supreme Court.

The new damages bid stems from a long-running dispute between the pharmaceutical giants over the drug — which is used to treat nerve pain, among other uses — trails back to 2015 and is part of a larger tangle of litigation that also involves two other generic drug makers, Activis and Mylan, according to court...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!